At 35.73, the stock's Price to Earnings ratio is 0.79x less than the industry average, suggesting favorable growth potential.

The U.S. dollar's sharp decline in 2025 is hitting American travelers hard, raising vacation costs in Paris, London, Cancun, ...

Greif Inc. (GEF) divests Containerboard business to Packaging Corp. of America (PKG) for $1.8B in cash, expected to close by ...

A Benzinga poll pits Nvidia, Apple and Microsoft against each other to see which company will be the first to hit a $4 ...

Many were quick to point out that not all lifestyle creep is careless. “To me, lifestyle creep is when you decide you deserve ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

What Happened: In a recent Form 4 filing with the U.S. Securities and Exchange Commission on Monday, Mazzacco, Director at Krystal Biotech, acquired 5,000 stock options for KRYS with an exercise price ...

What Happened: Disclosed in a Form 4 filing on Monday with the U.S. Securities and Exchange Commission, Sutherland, Board Member at Krystal Biotech, executed a strategic derivative sale. This involved ...

Krystal Biotech shares are trading, exhibiting down of 0.0% and priced at $137.46 during Tuesday's morning. This values Janney's 0 shares at $0.

What Happened: A notable Form 4 filing on Monday with the U.S. Securities and Exchange Commission revealed that Meury, Chief Executive Officer at Incyte, exercised stock options for 0 shares of INCY, ...

What Happened: In a Form 4 filing with the U.S. Securities and Exchange Commission on Monday, Gangolli, Director at Krystal Biotech, acquired stock options for 5,000 shares of KRYS. These options ...

What Happened: Revealed in a Form 4 filing on Monday with the U.S. Securities and Exchange Commission, Rossi, Board Member at Krystal Biotech, strategically acquired stock options for 5,000 shares of ...